Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jörg Bäsecke

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|May 15, 2007
[Occlusion of the femoral arteries in de novo AML]Anke Ressel, Lorenz Trümper, Jörg Bäsecke
Revista Iberoamericana De Micologia|July 21, 2006
A case of pulmonary aspergillosis with lack of response to caspofunginReinhard Rüchel, Christine Perske, Bertram Glass, et al.
European Journal of Haematology|March 27, 2015
Primary osteomyelofibrosis and an XX-male genotypeJulie Schanz, Detlef Haase, Peter Steuernagel, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 13, 2005
[Polycythemia vera and D-dimer-negative thromboembolism]Jörg Bäsecke, Imme Conradi, Carsten P Bramlage, et al.
Leukemia Research|March 17, 2006
Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adultsJörg Bäsecke, Martina Podleschny, Robert Clemens, et al.
Deutsche Medizinische Wochenschrift (1946)|December 14, 2018
[ELITE study - Nutrition, lifestyle and individual information for the prevention of stroke, dementia and heart attack - Study design and cardiovascular status]Stephan Lüders, Bastian Schrader, Jörg Bäsecke, et al.
Leukemia & Lymphoma|December 29, 2004
AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiationJörg Bäsecke, Maike Schwieger, Frank Griesinger, et al.
Oncology Research and Treatment|April 13, 2023
Early versus Delayed Tumor-Specific Therapy and Survival in Patients with Lung Cancer: A Retrospective StudyRike Geiken-Weinstock, Anna K L Reyners, Frank Griesinger, et al.
Cancers|November 13, 2025
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung CancerRike Geiken-Weinstock, Frank Griesinger, Michael Metz, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Medizinische Klinik (Munich, Germany : 1983)|May 15, 2007
[Occlusion of the femoral arteries in de novo AML]Anke Ressel, Lorenz Trümper, Jörg Bäsecke
Revista Iberoamericana De Micologia|July 21, 2006
A case of pulmonary aspergillosis with lack of response to caspofunginReinhard Rüchel, Christine Perske, Bertram Glass, et al.
European Journal of Haematology|March 27, 2015
Primary osteomyelofibrosis and an XX-male genotypeJulie Schanz, Detlef Haase, Peter Steuernagel, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 13, 2005
[Polycythemia vera and D-dimer-negative thromboembolism]Jörg Bäsecke, Imme Conradi, Carsten P Bramlage, et al.
Leukemia Research|March 17, 2006
Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adultsJörg Bäsecke, Martina Podleschny, Robert Clemens, et al.
Deutsche Medizinische Wochenschrift (1946)|December 14, 2018
[ELITE study - Nutrition, lifestyle and individual information for the prevention of stroke, dementia and heart attack - Study design and cardiovascular status]Stephan Lüders, Bastian Schrader, Jörg Bäsecke, et al.
Leukemia & Lymphoma|December 29, 2004
AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiationJörg Bäsecke, Maike Schwieger, Frank Griesinger, et al.
Oncology Research and Treatment|April 13, 2023
Early versus Delayed Tumor-Specific Therapy and Survival in Patients with Lung Cancer: A Retrospective StudyRike Geiken-Weinstock, Anna K L Reyners, Frank Griesinger, et al.
Cancers|November 13, 2025
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung CancerRike Geiken-Weinstock, Frank Griesinger, Michael Metz, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Pageof 2